A phase II clinical trial has found dimethyltryptamine (DMT), one of the psychoactive components traditionally used in the Amazonian psychedelic ritual ayahuasca, might be a promising therapy for depression.
The psychedelic pharmaceutical company Small Pharma (now Cybin UK) sponsored and designed the trial, which was led by Dr David Erritzoe, a psychiatrist and neuroscientist at Imperial College London. The results were published in Nature this month.
.png?w=600)
